Overview
- Peptide (C)KVNRYFTMDFKHRH, corresponding to amino acid residues 474-487 of rat PAC1 receptor (Accession P32215). Intracellular, C-terminus.
- Mouse and rat brain and rat cerebellum lysates (1:500-1:2500).
- Western blot analysis of mouse brain (lanes 1 and 4), rat brain (lanes 2 and 5) and rat cerebellum (lanes 3 and 6) lysates:1-3. Anti-PACAP Receptor 1 (PAC1) Antibody (#AVR-003), (1:500).
4-6. Anti-PACAP Receptor 1 (PAC1) Antibody, preincubated with PACAP Receptor 1/PAC1 Blocking Peptide (#BLP-VR003).
- Rat brain sections (1:400).
Pituitary adenylate cyclase-activating polypeptide (PACAP, encoded by ADCYAP1) belongs a superfamily of structurally related peptide hormones, which include vasoactive intestinal peptide (VIP), glucagon, glucagon-like peptides, secretin, gastric inhibitory peptide and growth hormone-releasing hormone.
PACAP acts through PAC1, VPAC1 and VPAC2, initiating multiple signaling pathways1. PAC1 is a class B member of the G-protein coupled receptors (GPCRs) superfamily. Class B receptors are differentiated from Class A by a relatively large N-terminal ectodomain that is crucial to ligand recognition2.
PAC1R is mainly expressed on smooth muscle cells, neurons, endothelial cells and peritoneal macrophages3.
PAC1R is associated with posttraumatic stress disorder (PTSD) symptoms and psychophysiological markers of fear and anxiety4.
PAC1 receptor null mice demonstrate reduced anxiety-like behavior5. In addition, PAC1 overexpression can result in hydrocephalus- and schizophrenia-related neuropathology1.